|
| 36976644 | Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells. | | 2023 |
| 37947117 | Association Between Self-Rated Medication Adherence and Adverse Cardiovascular Outcomes in Patients With Hypertension. | | 2023 |
| 37855448 | Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. | | 2023 |
| 37820081 | Angiopoietin-like 3 inhibition and the liver: less is more? | | 2023 |
| 37819667 | Concordance of a High Lipoprotein(a) Concentration Among Relatives. | | 2023 |
| 36697324 | Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model. | | 2023 |
| 36936266 | The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. | BMJ Med | 2023 |
| 36473758 | Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia. | Atherosclerosis | 2023 |
| 36736292 | Using genetic association data to guide drug discovery and development: Review of methods and applications. | Am J Hum Genet | 2023 |
| 37294245 | Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. | JACC Heart Fail | 2023 |
| 36604244 | Counseling couples at risk of having a child with homozygous familial hypercholesterolemia - Clinical experience and recommendations. | | 2023 |
| 37101178 | Genetic evidence implicating natriuretic peptide receptor-3 in cardiovascular disease risk: a Mendelian randomization study. | | 2023 |
| 34931349 | Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. | British Journal of Clinical Pharmacology | 2022 |
| 35699189 | Low-Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific. | Journal of the American Heart Association | 2022 |
| 35948913 | Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups. | BMC Med | 2022 |
| 36210291 | Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. | Journal of Clinical Lipidology | 2022 |
| 36075246 | Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. | Lancet Diabetes and Endocrinology,The | 2022 |
| 36203939 | The potential of glucagon-like peptide-1 receptor agonists in heart failure. | Frontiers in Physiology | 2022 |
| 35361489 | Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study. | Atherosclerosis | 2022 |
| 35921096 | Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study. | JAMA Cardiology | 2022 |
| 35238894 | Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy. | Diabetes Care | 2022 |
| 35212585 | Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. | Expert Review of Clinical Immunology | 2022 |
| 34774485 | LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. | J Lipid Res | 2022 |
| 34774301 | Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. | Atherosclerosis | 2022 |
| 34936472 | Letter by Tromp et al Regarding Article, "Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland". | Arteriosclerosis, Thrombosis, and Vascular Biology | 2022 |
| 35331419 | Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia. | Journal of the American College of Cardiology | 2022 |
| 35103484 | Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization. | Circ Genom Precis Med | 2022 |
| 34392272 | The iterative lipid impact on inflammation in atherosclerosis. | Current Opinion in Lipidology | 2021 |
| 36654293 | Studies into the association between LDL-C lowering and cognitive function: time to forget about it? | | 2021 |
| 31752531 | PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. | European Journal of Preventive Cardiology | 2021 |
| 34298557 | Next-generation sequencing to confirm clinical familial hypercholesterolemia. | European Journal of Preventive Cardiology | 2021 |
| 34017863 | Downregulation of Endothelial Plexin A4 Under Inflammatory Conditions Impairs Vascular Integrity. | Frontiers in Cardiovascular Medicine | 2021 |
| 33691480 | ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2021 |
| 34004483 | Marked plaque regression in homozygous familial hypercholesterolemia. | Atherosclerosis | 2021 |
| 33560669 | The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives. | Current Opinion in Lipidology | 2021 |
| 33558525 | Publisher Correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. | Nat Commun | 2021 |
| 33601267 | Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia. | Atherosclerosis | 2021 |
| 34321507 | High density lipoproteins mediate in vivo protection against staphylococcal phenol-soluble modulins. | Scientific Reports | 2021 |
| 33147992 | Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2021 |
| 33402679 | Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. | Nat Commun | 2021 |
| 31422358 | Sudden cardiac death in families with premature cardiovascular disease. | Heart | 2020 |
| 32327106 | Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. | Journal of the American College of Cardiology | 2020 |
| 31801376 | Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2020 |
| 31848588 | The therapeutic age paradox coming to an end. | European Heart Journal | 2020 |
| 32363493 | Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. | Cardiovascular Drugs and Therapy | 2020 |
| 31950403 | Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association. | Journal of General Internal Medicine | 2020 |
| 31895433 | Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. | JAMA Cardiol | 2020 |
| 32057369 | Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. | Journal of the American College of Cardiology | 2020 |
| 32349563 | Gene-based therapy in lipid management: the winding road from promise to practice. | Expert Opinion on Investigational Drugs | 2020 |
| 31996024 | Taking One Step Back in Familial Hypercholesterolemia: Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2020 |